Fig 1.
Brief cessation (<30days) and permanent cessation (>30days) of DAPT in planned PCI and ad hoc PCI cohorts.
All four groups have p < 0.05.
Table 1.
Baseline characteristics and compliance in both planned and ad hoc PCI group.
Table 2.
Procedural characteristics and MACE.
Fig 2.
Cumulative incidence of non-compliance to DAPT at 12 months’ follow-up.
Dual antiplatelet therapy (DAPT), percutaneous coronary intervention (PCI).
Table 3.
Non-compliance of DAPT in planned PCI and ad hoc PCI cohorts.
Table 4.
Logistic regression analysis to assess the predictors for non-compliance to DAPT.